Lucatumumab

Lucatumumab
[[File:|frameless|220px|alt=|]]
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status	Investigational
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Lucatumumab is an experimental monoclonal antibody designed for the treatment of cancer. It targets CD40, a co-stimulatory protein found on the surface of many immune system cells as well as some cancer cells. Lucatumumab is being investigated for its potential use in the treatment of various types of cancers, including multiple myeloma, non-Hodgkin lymphoma, and chronic lymphocytic leukemia.

Mechanism of Action

Lucatumumab works by binding to the CD40 molecule on the surface of tumor cells and immune cells. This binding can lead to the activation of antitumor immune responses and may also directly induce apoptosis (programmed cell death) in tumor cells. The CD40 receptor is an important player in the activation of both innate and adaptive immune responses, making it a promising target for cancer therapy.

Clinical Trials

Lucatumumab has been evaluated in several clinical trials. Early-phase trials have assessed its safety, tolerability, and preliminary efficacy in patients with various hematologic malignancies. The results from these trials have provided insights into the optimal dosing schedules and potential side effects, which include infusion reactions and cytokine release syndrome.

Development and Regulatory Status

As of the last update, Lucatumumab is still in the investigational stages and has not yet received approval from regulatory bodies such as the Food and Drug Administration (FDA) in the United States. Its development is being monitored by researchers and clinicians who are exploring its full potential and safety profile in a broader range of cancer types.

Potential Impact and Future Directions

If successful, Lucatumumab could offer a new therapeutic option for patients with cancers that express CD40. Ongoing research and future clinical trials will determine its place in cancer therapy, particularly in combination with other therapeutic agents like chemotherapy, radiotherapy, and other immunotherapies.

See Also

• Monoclonal antibodies
• Immunotherapy
• Cancer treatment

   This article is a medical stub. You can help WikiMD by expanding it!